evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/geneAliases/7,gene/geneAliases/8,gene/geneAliases/9,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract,articles/11/pmid,articles/11/title,articles/11/journal,articles/11/pubDate,articles/11/volume,articles/11/issue,articles/11/pages,articles/11/authors,articles/11/elocationId,articles/11/link,articles/11/reference,articles/11/abstract,articles/12/pmid,articles/12/title,articles/12/journal,articles/12/pubDate,articles/12/volume,articles/12/issue,articles/12/pages,articles/12/authors,articles/12/elocationId,articles/12/link,articles/12/reference,articles/12/abstract,articles/13/pmid,articles/13/title,articles/13/journal,articles/13/pubDate,articles/13/volume,articles/13/issue,articles/13/pages,articles/13/authors,articles/13/elocationId,articles/13/link,articles/13/reference,articles/13/abstract,articles/14/pmid,articles/14/title,articles/14/journal,articles/14/pubDate,articles/14/volume,articles/14/issue,articles/14/pages,articles/14/authors,articles/14/elocationId,articles/14/link,articles/14/reference,articles/14/abstract,articles/15/pmid,articles/15/title,articles/15/journal,articles/15/pubDate,articles/15/volume,articles/15/issue,articles/15/pages,articles/15/authors,articles/15/elocationId,articles/15/link,articles/15/reference,articles/15/abstract,articles/16/pmid,articles/16/title,articles/16/journal,articles/16/pubDate,articles/16/volume,articles/16/issue,articles/16/pages,articles/16/authors,articles/16/elocationId,articles/16/link,articles/16/reference,articles/16/abstract,articles/17/pmid,articles/17/title,articles/17/journal,articles/17/pubDate,articles/17/volume,articles/17/issue,articles/17/pages,articles/17/authors,articles/17/elocationId,articles/17/link,articles/17/reference,articles/17/abstract,articles/18/pmid,articles/18/title,articles/18/journal,articles/18/pubDate,articles/18/volume,articles/18/issue,articles/18/pages,articles/18/authors,articles/18/elocationId,articles/18/link,articles/18/reference,articles/18/abstract,articles/19/pmid,articles/19/title,articles/19/journal,articles/19/pubDate,articles/19/volume,articles/19/issue,articles/19/pages,articles/19/authors,articles/19/elocationId,articles/19/link,articles/19/reference,articles/19/abstract,articles/20/pmid,articles/20/title,articles/20/journal,articles/20/pubDate,articles/20/volume,articles/20/issue,articles/20/pages,articles/20/authors,articles/20/elocationId,articles/20/link,articles/20/reference,articles/20/abstract
16607,GENE_BACKGROUND,,"The ERBB3 (HER3) gene encodes a receptor tyrosine kinase that is a member of the Epidermal Growth Factor Receptor Family (EGFR) of proteins (PMID: 19536107, 11252954, 19208461). ERBB3 is unique in that it has limited kinase activity, approximately 1000 fold less than its family member, EGFR (PMID: 8389462, 8058764, 20351256). Thereby, ERBB3 cannot form homodimers (PMID: 15225657), and thus is not transforming on its own nor by constant stimulation by its ligands neuregulin-1 (NRG-1) and NRG-2 (PMID: 19208461) in the absence of a dimer partner (PMID: 8632008). Yet, ERBB3 has sufficient kinase activity to bind its preferred heterodimer partner, ERBB2 (PMID: 20351256, 20007378, 10220407, 9130710) and catalyze autophosphorylation of its C-terminal intracellular tail, which recruits adapter proteins that potently initiate mitogenic cascades, including the PI3K/AKT/mTOR pathway (PMID: 7515147, 8026468, 8264617), RAS/MAPK, SRC and STAT pathways (PMID: 12853564, 22785351). Cell line, xenograft and transgenic mouse data demonstrate that ERBB2-amplified cells exquisitely rely on ERBB3 to drive proliferation and survival (PMID: 12853564, 24651011, 19536107). Moreover, ERBB3 feedback upregulation, localization changes and ligand overexpression contribute to resistance to ERBB or PI3K/AKT/mTOR inhibitors (PMID: 24520092, 24651011, 19536107). Increased ERBB3 levels correlate with tumor progression and poor prognosis in some cancers (PMID: 20179223, 20816829). ERBB3 is mutated in approximately 10% of gastric, bladder, uterine and colorectal cancers, and in other cancers, including breast cancer, at frequencies <5% (PMID: 23680147). A few mutants have been functionally characterized as oncogenic in the presence of ERBB2 (PMID: 23680147), including the most common mutant allele, V104M. There are no FDA approved ERBB3 inhibitors, but clinical trials are underway for a variety of ERBB3 targeting compounds.",,2017-04-18,,2065,ERBB3,erb-b2 receptor tyrosine kinase 3,True,ENST00000267101,NM_001982.3,ErbB-3,p180-ErbB3,p45-sErbB3,LCCS2,c-erbB-3,c-erbB3,p85-sErbB3,MDA-BF-1,erbB3-S,HER3,False,8026468,Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera.,The EMBO journal,0001-06-15,13,12,2831-41,Prigent SA et al,,,0001-06-15,,12853564,The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.,Proceedings of the National Academy of Sciences of the United States of America,2018-07-22T20:03:00,100,15,8933-8,Holbro T et al,,,0001-07-22,,10220407,0001-05-01,Proceedings of the National Academy of Sciences of the United States of America,0001-04-27,96,9,4995-5000,Klapper LN et al,,,0001-04-27,,15225657,ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.,FEBS letters,2018-07-02T20:04:00,569,2001-01-03,332-6,Berger MB et al,,,2002-01-03,,9130710,"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.",The EMBO journal,0001-04-01,16,7,1647-55,Graus-Porta D et al,,,0001-04-01,,24651011,ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.,Cancer cell,2018-03-17T20:14:00,25,3,282-303,Arteaga CL et al,doi: 10.1016/j.ccr.2014.02.025,,2018-03-17T03:03:00,,20816829,"The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.",Seminars in cell &amp; developmental biology,2017-12-01T20:10:00,21,9,944-50,Amin DN et al,doi: 10.1016/j.semcdb.2010.08.007,,0001-12-01,,7515147,ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor.,Molecular and cellular biology,0001-06-01,14,6,3550-8,Soltoff SP et al,,,0001-06-01,,23680147,Oncogenic ERBB3 mutations in human cancers.,Cancer cell,2018-05-13T20:13:00,23,5,603-17,Jaiswal BS et al,doi: 10.1016/j.ccr.2013.04.012,,0001-05-13,,20179223,"HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.",Clinical cancer research : an official journal of the American Association for Cancer Research,2018-03-01T20:10:00,16,5,1373-83,Campbell MR et al,doi: 10.1158/1078-0432.CCR-09-1218,,0001-03-01,,8632008,Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2.,The Journal of biological chemistry,0001-02-16,271,7,3884-90,Zhang K et al,,,0001-02-16,,20351256,ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.,Proceedings of the National Academy of Sciences of the United States of America,2018-04-27T20:10:00,107,17,7692-7,Shi F et al,doi: 10.1073/pnas.1002753107,,0001-04-27,,8264617,"Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members.",Molecular and cellular biology,0001-01-01,14,True,492-500,Fedi P et al,,,2018-01-01T05:00:00,,8389462,Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor.,Proceedings of the National Academy of Sciences of the United States of America,0001-06-01,90,11,5001-5,Knighton DR et al,,,0001-06-01,,20007378,Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.,Proceedings of the National Academy of Sciences of the United States of America,2017-12-22T20:09:00,106,51,21608-13,Jura N et al,doi: 10.1073/pnas.0912101106,,0001-12-22,,19208461,ErbB receptors and signaling pathways in cancer.,Current opinion in cell biology,2018-04-01T20:09:00,21,2,177-84,Hynes NE et al,doi: 10.1016/j.ceb.2008.12.010,,0001-04-01,,11252954,Untangling the ErbB signalling network.,Nature reviews. Molecular cell biology,2018-02-01T20:01:00,2,2,127-37,Yarden Y et al,,,0001-02-01,,8058764,"Linkage of a human brain malformation, familial holoprosencephaly, to chromosome 7 and evidence for genetic heterogeneity.",Proceedings of the National Academy of Sciences of the United States of America,0001-08-16,91,17,8102-6,Muenke M et al,,,0001-08-16,,19536107,Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.,Nature reviews. Cancer,2018-07-01T20:09:00,9,7,463-75,Baselga J et al,doi: 10.1038/nrc2656,,0001-07-01,,22785351,"The ERBB network: at last, cancer therapy meets systems biology.",Nature reviews. Cancer,2018-07-12T20:12:00,12,8,553-63,Yarden Y et al,doi: 10.1038/nrc3309,,0001-07-12,,24520092,Molecular pathways: HER3 targeted therapy.,Clinical cancer research : an official journal of the American Association for Cancer Research,2018-03-15T20:14:00,20,6,1410-6,Gala K et al,doi: 10.1158/1078-0432.CCR-13-1549,,0001-03-15,
16606,GENE_SUMMARY,,ERBB3 encodes a member of the EGFR family of receptor tyrosine kinases that signals through the pro-oncogenic MAP- and PI3-kinase pathways. ERBB3 is recurrently mutated in gastric and colon cancer.,,2017-04-18,,2065,ERBB3,erb-b2 receptor tyrosine kinase 3,True,ENST00000267101,NM_001982.3,ErbB-3,p180-ErbB3,p45-sErbB3,LCCS2,c-erbB-3,c-erbB3,p85-sErbB3,MDA-BF-1,erbB3-S,HER3,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
